Replication-Competent Controlled Herpes Simplex Virus

被引:10
|
作者
Bloom, David C. [1 ]
Feller, Joyce [1 ]
McAnany, Peterjon [1 ]
Vilaboa, Nuria [2 ,3 ]
Voellmy, Richard [4 ,5 ]
机构
[1] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA
[2] Hosp Univ La Paz, IdiPAZ, Madrid, Spain
[3] CIBER Bioingn Biomat & Nanomed, Barcelona, Spain
[4] HSF Pharmaceut SA, La Tour De Peilz, Switzerland
[5] Univ Florida, Coll Vet Sci, Dept Physiol Sci, Gainesville, FL USA
关键词
SHOCK TRANSCRIPTION FACTOR; HEAT-SHOCK; SPATIOTEMPORAL CONTROL; PREEXISTING IMMUNITY; ECDYSONE RECEPTOR; GENE SWITCHES; EXPRESSION; VECTOR; RECOMBINANT; PROTEINS;
D O I
10.1128/JVI.01667-15
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We present the development and characterization of a replication-competent controlled herpes simplex virus 1 (HSV-1). Replication-essential ICP4 and ICP8 genes of HSV-1 wild-type strain 17syn+ were brought under the control of a dually responsive gene switch. The gene switch comprises (i) a transactivator that is activated by a narrow class of antiprogestins, including mifepristone and ulipristal, and whose expression is mediated by a promoter cassette that comprises an HSP70B promoter and a transactivator-responsive promoter and (ii) transactivator-responsive promoters that drive the ICP4 and ICP8 genes. Single-step growth experiments in different cell lines demonstrated that replication of the recombinant virus, HSV-GS3, is strictly dependent on an activating treatment consisting of administration of a supraphysiological heat dose in the presence of an antiprogestin. The replication-competent controlled virus replicates with an efficiency approaching that of the wild-type virus from which it was derived. Essentially no replication occurs in the absence of activating treatment or if HSV-GS3-infected cells are exposed only to heat or antiprogestin. These findings were corroborated by measurements of amounts of viral DNA and transcripts of the regulated ICP4 gene and the glycoprotein C (gC) late gene, which was not regulated. Similar findings were made in experiments with a mouse footpad infection model. IMPORTANCE The alphaherpesviruses have long been considered vectors for recombinant vaccines and oncolytic therapies. The traditional approach uses vector backbones containing attenuating mutations that restrict replication to ensure safety. The shortcoming of this approach is that the attenuating mutations tend to limit both the immune presentation and oncolytic properties of these vectors. HSV-GS3 represents a novel type of vector that, when activated, replicates with the efficiency of a nonattenuated virus and whose safety is derived from deliberate, stringent regulation of multiple replication-essential genes. By directing activating heat to the region of virus administration, replication is strictly confined to infected cells within this region. The requirement for antiprogestin provides an additional level of safety, ensuring that virus replication cannot be triggered inadvertently. Replication-competent controlled vectors such as HSV-GS3 may have the potential to be superior to conventional attenuated HSV vaccine and oncolytic vectors without sacrificing safety.
引用
收藏
页码:10668 / 10679
页数:12
相关论文
共 50 条
  • [11] Treatment of metastatic brain tumors with a replication-competent multimutated herpes simplex virus-1
    Toda, M
    Uyemura, K
    Kawase, T
    Rabkin, SD
    Martuza, RL
    NEURAL DEVELOPMENT-BOOK, 1999, 2 : 521 - 525
  • [12] Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector
    Yoon, SS
    Carroll, NM
    Chiocca, EA
    Tanabe, KK
    ANNALS OF SURGERY, 1998, 228 (03) : 366 - 372
  • [13] Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector - Discussion
    Eberlein, TJ
    Tanabe, KK
    Daly, JM
    ANNALS OF SURGERY, 1998, 228 (03) : 372 - 374
  • [14] Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain
    Andrew E. Radbill
    Alyssa T. Reddy
    James M. Markert
    J. Michael Wyss
    Martin M. Pike
    N. Shastry Akella
    Niteesh Bharara
    G. Yancey Gillespie
    Journal of NeuroVirology, 2007, 13 : 118 - 129
  • [15] The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer
    Stiles, BM
    Bhargava, A
    Adusumilli, PS
    Stanziale, SF
    Kim, TH
    Rusch, VW
    Fong, YM
    SURGERY, 2003, 134 (02) : 357 - 364
  • [16] Replication-competent Herpes Simplex Virus Retargeted to HER2 as Therapy for High-grade Glioma
    Gambini, Eleonora
    Reisoli, Elisa
    Appolloni, Irene
    Gatta, Valentina
    Campadelli-Fiume, Gabriella
    Menotti, Laura
    Malatesta, Paolo
    MOLECULAR THERAPY, 2012, 20 (05) : 994 - 1001
  • [17] A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine
    Brittle, Elizabeth E.
    Wang, Fushan
    Lubinski, John M.
    Bunte, Ralph M.
    Friedman, Harvey M.
    JOURNAL OF VIROLOGY, 2008, 82 (17) : 8431 - 8441
  • [18] Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain
    Radbill, Andrew E.
    Reddy, Alyssa T.
    Markert, James M.
    Wyss, J. Michael
    Pike, Martin M.
    Akella, N. Shastry
    Bharara, Niteesh
    Gillespie, G. Yancey
    JOURNAL OF NEUROVIROLOGY, 2007, 13 (02) : 118 - 129
  • [19] Replication-competent herpes simplex virus type 1 mutant expressing an autofluorescent glycoprotein H fusion protein
    Lorentzen, EU
    Eing, BR
    Hafezi, W
    Manservigi, R
    Kühn, JE
    INTERVIROLOGY, 2001, 44 (04) : 232 - 242
  • [20] Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus
    Todo, T
    Rabkin, SD
    Sundaresan, P
    Wu, AG
    Meehan, KR
    Herscowitz, HB
    Martuza, RL
    HUMAN GENE THERAPY, 1999, 10 (17) : 2741 - 2755